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Summary A comparison of the cytotoxic effectiveness of adriamycin incorporated into ion exchange
microspheres with conventional chemotherapeutic use of adriamycin was carried out in a rat tumour model.
Drug microspheres were targeted to the tumours by embolisation into the arterial supply of the hind limb
bearing the tumour. Microspheres were found to embolise in tumour tissue at concentrations of up to 39
times that of the surrounding normal tissue. As a result, adriamycin microsphere therapy was found to retard
significantly (P<0.01) tumour growth rates compared to growth rates associated with similar doses of
adriamycin delivered as free drug rather than bound to controlled release microspheres. Equivalent sham
microsphere treatments showed no significant difference in tumour growth rates compared with the control
group. Adriamycin loaded on to ion exchange microspheres holds strong potential for treatment of human
malignancy.
The systemic toxicity arising from the non-specificity of most
cytotoxic drugs for tumour tissue, as opposed to normal
tissue, restricts the efficacy of cancer chemotherapy. Conse-
quently it would be advantageous to concentrate these drugs
in the tumour bearing organ thus reducing systemic exposure
to the drug. One way this can be achieved is by targeting
drug loaded microspheres to the tumour via its arterial
blood supply, whereupon the drug is slowly released into the
immediate tumour environment.
Many investigations have centred on the use of a variety
of microparticles for the targeting of drugs. These micropar-
ticles have included liposomes (Gregoriadis & Neerunjin,
1975), albumin microspheres (Tomlinson, 1983) and a variety
of polymeric systems (Tokes et al., 1982; Couvreur et al.,
1980; Wakiyama et al., 1981) all conjugated with different
drugs.
Ion exchange resin microspheres have rarely been used
although hydrophilic albumin and dextran microspheres con-
taining weakly acidic ion exchange groups have been used
for transporting drugs (Goldberg et al., 1984). Since 1982 we
have investigated the use of ion exchange microspheres as
vehicles for the parenteral transport of radioactive isotopes
as a method for administering high doses of regional organ
radiotherapy (Chamberlain et al., 1983). This has included
the development of a technique for the preferential shunting
of microspheres to tumour tissue using vasoactive agents
(Burton et al., 1985). The technique is now being used in
phase 1 and 2 studies in patients with liver metastases at
Royal Perth Hospital. There have been no detectable
problems associated with the use of these ion exchange
microspheres in either animals or humans. As the micro-
spheres used to transport the radioactive isotopes used for
radiotherapy are very similar to those used to carry adria-
mycin, it is axiomatic that it is also possible to deliver high
concentrations of adriamycin microspheres into the micro-
circulation of the metastases.
In a previous study we described the payload and release
characteristics of a strongly acidic ion exchange microsphere
as a potential vehicle for the transport of adriamycin (Jones
et al., 1989). These microspheres were manufactured with
drug contents of up to 35% W/W and equilibrium drug
concentration for the adriamycin microspheres was similar to
serum levels encountered with conventional adriamycin
chemotherapy. When embolised within the microvasculature,
drug release from microspheres is controlled by the rate of
drug diffusion away from the microsphere surface into the
surrounding tissue (Goldberg et al., 1984). Adriamycin
release would therefore be sustained in vivo as an embolised
microsphere is in a stagnant, steady state environment.
Correspondence: M.A. Burton.
This present study was designed to compare the cytotoxic
effectiveness of adriamycin containing ion exchange micro-
spheres targeted to experimental rat tumours as opposed to
conventional chemotherapeutic use of adriamycin.
Materials and methods
Tracer microspheres
The ratio of embolisation of microspheres in tumour tissue
was compared to the entrapment of microspheres in normal
tissue using blood flow tracer microspheres (New England
Nuclear Co., Boston, USA). These microspheres were
16.4+0.2,pm in diameter and were labelled with cobalt-57 to
an initial specific activity of 84d.p.m. per sphere. They were
suspended in a 10% dextran solution before use.
Adriamycin microspheres
Adriamycin loaded ion exchange microspheres with drug
payloads of 39.9% and equilibrium concentrations of
2.1 x 10 -M were prepared in our laboratories. The ion
exchange microspheres had a mean diameter of 20.5 +2.5pm
and were stored at -10°C to prevent microsphere clumping.
A batch manufacturing procedure was used for attachment
of adriamycin to Aminex A-6 resin (Bio-Rad, New York).
This involved the slurrying of the ion exchange resin with
adriamycin (30mgml-1) for 12h. The drug laden resin was
then filtered, washed and suspended in distilled water (Jones
et al., 1989).
Rat model experiments
Adult D.A. rats of mixed sex (200-250g) had small segments
(I mm3) of salivary adenocarcinoma implanted, intra-
muscularly, into the left and right hind limbs. This tumour
has been extensively utilised by our group and has been
described elsewhere (Stribley et al., 1983).
Tumour size was measured using calibrated callipers and
expressed as the product of the minimal and maximal
horizontal dimensions (cm). Measurements were taken daily
from 7 days after tumour implantation.
Bloodflow experiments
Blood flow experiments were carried out in eight rats at 10-
22 days after tumour implantation to obtain a range of
tumour sizes. Rats were anaesthetised with intrahepatic
Nembutal and a catheter was introduced into the ascending
aorta via a right carotid cannulation. A suspension of
8 x 105 tracer microspheres was thoroughly mixed through a
three-way tap and injected into the aorta over 10s.
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Each animal was killed approximately 5min after the
microsphere injection to ensure total trapping of the
microspheres within the tissue. Both hind limbs and kidneys
were removed and fixed in 10% buffered formalin. The
resulting specific activity of tumour tissue was obtained by
sampling the whole tumour and counting samples in a three-
channel gamma cQunter. Normal muscle tissue samples were
also taken at random from each hind limb and their mean
specific activity was calculated. The ratio of blood flow to
tumour tissue as opposed to normal muscle tissue (T/N
ratio) was then calculated from a comparison of the mean
specific activities of each tissue compartment.
The efficiency of microsphere mixing during injection was
determined for each experiment. The left and right kidneys
from each rat were counted and the specific activity of each
kidney calculated. If the difference in the specific activity
between the two kidneys divided by the specific activity of
both kidneys combined was greater than 0.1, then the results
were discarded as this indicated poor mixing of the micro-
spheres in the blood stream.
Therapeutic studies
These experiments were initiated to assess the efficacy of
adriamycin microsphere therapy as compared with conven-
tional drug therapy. Seven rats were used for each of the
seven treatment groups. Each treatment was commenced 3
days after the hind limb tumour size reached 0.2cm2.
The treatment groups were: (a) control (no treatment); (b)
3.0mgkg-1 adriamycin delivered into the aorta as drug
microspheres; (c) 4.5mgkg-1 adriamycin delivered into the
aorta as drug microspheres; (d) 3.0mgkg- 1 adriamycin
delivered into the aorta as the free drug; (e) 4.5mgkg-1
adriamycin delivered into the aorta as the free drug; (f)
2.0mgkg-1 sham microspheres (equivalent to the number of
microspheres in treatment (b); (g) 3.0mgkg-1 sham micro-
spheres (equivalent to the number of microspheres in treat-
ment (c)). All treatments were carried out by injection,
upstream, into the descending aorta directly above the
femoral artery bifurcation. This enabled microspheres to be
lodged only in the hind limbs and tail. In the case of
microsphere treatments, thorough mixing through a three-
way tap was carried out before injection. Tumour growth
rate was monitored for 7 days after injection.
Statistics
The mean and standard deviation of daily tumour sizes was
calculated for each treatment group and plotted against time.
Curves for each treatment group were transformed by taking
the log of tumour size. Linear regression analysis was
performed on the resulting curves. Data for each of the six
treatment groups were then compared with the control group
by the comparison of linear regressions technique. This
technique was also used to compare both the free drug
treatment curves with the drug microsphere treatment
curves.
Table I Ratios of tracer micro-
spheres embolised in tumour
tissue compared to normal muscle
tissue for different sized rat
tumours
Tumour size
(cm2) TIN ratio
0.25 9.8
0.56 30.2
0.80 38.9
1.04 6.9
1.44 10.7
2.40 4.4
4.80 6.8
6.12 8.9
Mean 14.6+ 12.7
Table II Mean daily tumour sizes for rat treatment - groups A-G
Groups
Day A B C D E F G
1 0.29
(0.09)
2 0.62
(0.16)
3 0.85
(0.27)
4 1.13
(0.16)
5 1.95
(0.41)
6 3.47
(1.12)
7 5.73
(0.89)
8 6.20
(0.79)
9 7.58
(0.25)
10 8.85
(0.21)
0.28
(0.09)
0.57
(0.22)
0.75
(0.28)
0.65
(0.31)
1.56
(0.60)
2.81
(1.20)
3.94
(1.70)
4.34
(1.76)
0.29 0.39
(0.07) (0.05)
0.91
(0.24)
1.02 0.99
(0.56) (0.27)
0.83 1.88
(0.59) (0.31)
0.75 2.47
(0.70) (0.49)
3.21
(0.63)
3.36
(0.61)
1.50 4.93
(0.94) (0.42)
1.85 5.75
(0.95) (0.66)
2.32 6.27
(1.39) (0.93)
0.49
(0.14)
0.88
(0.29)
1.26
(0.44)
1.71
(0.49)
2.28
(0.47)
3.28
(1.00)
3.81
(0.71)
5.63
(0.22)
5.70
(0.54)
7.73
(0.83)
0.33
(0.12)
0.56
(0.16)
0.89
(0.34)
1.04
(0.23)
1.71
(0.64)
3.11
(1.15)
5.04
(1.07)
6.62
(0.43)
7.87
(0.49)
9.38
(0.15)
0.35
(0.07)
0.60
(0.09)
0.82
(0.16)
1.40
(0.69)
2.18
(0.76)
3.09
(0.85)
4.91
(0.73)
6.05
(0.77)
7.68
(0.63)
9.53
(1.18)
Standard deviation of the mean in parentheses.
n=7 for each group.
between the log of tumour size and time for all the
transformed curves. Also, the rates of tumour growth for
both the microsphere and free drug treatments (b,c,d and e)
were significantly slower (P<0.05) than for the control.
More importantly, the tumour growth rates associated with
both drug microsphere treatments (b and c) were signifi-
cantly slower (P<0.01) than the corresponding free drug
treatments (d and e). There was no significant difference in
the tumour growth rate for either of the sham microsphere
treatments (f and g) compared to the control.
Discussion
Results
The results in Table I represent the T/N ratios for a number
of different sized tumours. There was a wide range of T/N
ratios between the tumours (mean: 14.6+ 12.7) but invariably
there was a greater concentration of microspheres lodged in
the tumour compared to the normal tissue. There was no
significant association found between tumour size and T/N
ratio.
The mean+s.d. daily tumour sizes for all treatment groups
are expressed in Table II. Standard deviations of the mean
daily tumour sizes for both the drug microsphere treatments
were usually larger than those encountered in the free drug
and control treatments. This arises from a wide variation in
tumour response to the drug microsphere treatments.
There was a significant association (P <0.05) shown
The results obtained in the blood flow experiments show
that the arterial blood supply to tumours implanted in the
hind limb is greater than that of the surrounding muscle.
These experiments demonstrate that adriamycin loaded micro-
spheres can achieve concentrations in the tumour tissue of
up to 39 times that in the normal muscle tissue. This tumour
targeting of drug microspheres minimises systemic toxicity
while optimising tumour exposure to adriamycin. As a result,
higher doses of adriamycin can be used than are common in
conventional chemotherapy. Results from the therapeutic
study demonstrated enhanced in vivo growth inhibition in the
implanted tumours for adriamycin delivered in the
microspheres. An illustration of this enhanced activity is
evident in the lower tumour growth rate observed for the
3.0mgkg-1 adriamycin microsphere treatment even when
compared with the higher free drug dose of 4.5mgkg-1
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the microsphere drug treatments. It is likely that this is a
result of large variations in the T/N ratios observed between
tumours. Therefore, in the microsphere drug treatments, the
difference in drug microsphere concentration between
tumours would be substantial, resulting in the large tumour
response differential.
The enhanced activity was shown to result exclusively
from the provision of adriamycin directly into the tumour
environment. Neither sham experiment, introducing drug-
free microspheres, demonstrated a significant response
against the implanted tumours. The embolisation of the
tumour vasculature by the relatively small number of micro-
spheres was not sufficient to influence tumour growth.
Ion exchange microspheres have an advantage over other
drug carriers, such as albumin microspheres, in that they do
not exhibit an initial 'burst' release of drug. This situation
arises because adriamycin is released from a microsphere by
an exchange of blood borne cations, such as Na+, K+, Ca2+
and Mg2+, with adriamycin entrapped within a microsphere.
Released adriamycin quickly comes into equilibrium with
drug still bound to an embolised microsphere. Consequently,
the rate of adriamycin release is largely dependent on the
diffusion of drug away from, and counterions towards, the
microspheres. Because this is a steady state situation, the
drug should be released at a near constant rate.
Ion exchange microspheres show little adverse immuno-
logical reactivity over extended time periods. The cation
exchange microspheres used in this study have previously
been used by us to target radioisotopes to hepatic tumours
for the purpose of internal radiotherapy. Large numbers of
these microspheres have been embolised in dog livers for
significantly 4 years with only minimal histological changes
being detected. Therefore, after the total load of adriamycin
has been released from drug microspheres, there will be no
long-term toxic effects arising from the remaining ion
exchange microspheres.
The above experiments demonstrate that adriamycin deli-
vered within an ion exchange carrier has a significantly
greater inhibition of tumour growth than the same dose of
the drug delivered into the same site but given as the free
drug. However, the real advantage of drug targeted adriamy-
cin is likely to be far greater than is highlighted by these
experimental results.
The reason for this is as follows: As the dose limiting
factor for adriamycin is systemic toxicity (i.e. cardiac toxi-
city, myelosuppression, etc.), it is possible to administer far
greater absolute drug doses by enclosing the drug within a
microsphere environment and thus effectively shielding the
systemic circulation from the drug. When adriamycin is
released from the microsphere environment in order to come
into a concentration equilibrium with the surrounding tissue
fluids, it rapidly becomes bound to the local tumour tissues,
thereby further preventing systemic exposure. Therefore, not
only can the adriamycin be selectively delivered to the
tumour, but the absolute amount of the drug able to be
given will be greatly increased. When comparing the anti-
tumour effect, the relevant comparison with adriamycin
given by either systemic administration or regional perfusion
is the much greater adriamycin/microsphere dose that results
in the same level of systemic toxicity.
Conclusions
It has been demonstrated that adriamycin entrapped within
ion exchange microspheres shows significantly greater
tumour growth inhibition than when administered as the free
drug.
These adriamycin loaded ion exchange microspheres have
a potential application in the treatment of metastatic cancer.
Further work is required to determine the in vivo release
characteristics of these microspheres in different organs.
Adriamycin was kindly supplied by Dr C. Arblzastec iromii ['-rinitalfia
Carlo Erba. We would also like to acknowledge the assistance of the
Royal Perth Hospital Research Foundation and the Research Centre
staff.
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